By M. Marin
OTCQB: AINMF
READ THE FULL AINMF RESEARCH REPORT
Benefits of NetraMark’s AI de-risking solutions for clinical research
NetraMark views Executive Order positively …
NetraMark (OTCQB: AINMF), an AI company developing AI and Machine Learning (ML) solutions to help optimize pharmaceutical clinical research trial activities, shared its positive view of the Administration's April 18, 2026, publication of “Accelerating Medical Treatments for Serious Mental Illness” outlining federal actions designed to accelerate and expand clinical development of psychedelic drug programs and other emerging CNS therapeutics for certain investigational psychedelic drugs to treat serious mental illness. With about 8 million U.S. adults on prescription medication treating serious mental illness, measures intended to support responsible development include FDA review prioritization mechanisms for psychedelic drugs that have received Breakthrough Therapy designation and expected collaboration among multiple government agencies, among others.
The company believes this underscores a broader shift in mental health drug development. At the same time, accelerated interest in novel mechanisms requires rigorous modern clinical trial design, particularly in central nervous system (CNS) indications. The company’s initial focus is on the CNS (AINMF just published a related paper) and oncology spaces, where the relative percentages of drugs approved after clinical development is low. Over time, NetraMark expects to expand its focus to a range of other medical indications.
Psychedelic trials are among the most methodologically sensitive, according to AINMF, with heterogeneity, expectancy effects, and placebo response often obscuring treatment effects. NetraMark’s proprietary NetraAI platform is designed to address these challenges by identifying explainable patient subpopulations that might produce differential treatment response. NetraAI supports development of prospectively testable hypotheses and seeks to optimize trial designs. NetraMark believes that advanced, explainable analytics will become increasingly important to help sponsors optimize studies and obtain regulatory approval.
Consistent with advancing its opportunities in the CNS space, last month AINMF signed a new contract with a leading global biopharmaceutical company developing innovative treatments for psychiatric and neurological disorders to analyze data from the client’s Phase 2 clinical trial for depression. The aim is to leverage NetraMark’s platform to analyze the Phase 2 dataset to identify patient subpopulations most likely to benefit from treatment and provide insights that may inform the client’s future study design.
In the oncology space, NetraMark announced a strategic research collaboration with Fondazione per la Medicina Personalizzata (FMP) to analyze FMP’s ROME Phase II oncology trial dataset (NCT04591431) using NetraMark’s proprietary NetraAI platform, with the objective of identifying clinically actionable insights that may inform future precision-oncology strategies and clinical trial design. In addition to leveraging NetraAI’s capabilities to uncover clinically actionable insights for FMP’s ROME program, the collaboration is also expected to enable NetraMark to advance and refine its platform and strengthen its ability to support future clinical trial design, biomarker development, and strategies for a potentially growing client base.
The FMP agreement follows multiple partnerships NetraMark formed in 2025, expected to contribute to backlog and revenue. For example, NetraMark completed global Contract Research Organization (CRO) Worldwide Clinical Trial’s onboarding and quality assurance process in mid-October following their execution of a master services agreement in April 2025 to introduce a new service offering for Worldwide's customers powered by NetraMark's NetraAI platform to optimize clinical trial efficiencies. Worldwide Clinical Trials is a full-service global CRO with a footprint that reaches more than 60 countries and about 30 years of clinical experience. Its focus on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease aligns with NetraMark’s focus on CNS and the oncology space. Other contracts include Asklepion Pharmaceuticals and AlgoTherapeutix, among others, as AINMF continues to build awareness of its capabilities, with contracts averaging US$200K–$300K value.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.